Proxy advisory firm Glass Lewis recommended on Friday that Cephalon (CEPH.O) shareholders oppose an attempt by Valeant Pharmaceuticals (VRX.TO) to replace the U.S. drugmaker's board of directors.
Cephalon, Inc. is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Shares of CEPH traded higher by 0.16% or $0.12/share to $76.75. In the past year, the shares have traded as low as $54.15 and as high as $77.59. On average, 2785210 shares of CEPH exchange hands on a given day and today's volume is recorded at 783941.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 0.1% or $-0.05/share to $52.51. In the past year, the shares have traded as low as $13.67 and as high as $55.00. On average, 2724000 shares of VRX exchange hands on a given day and today's volume is recorded at 1276928.
Source
